SCM
SUPN icon

Sterling Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Sterling Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2K Sell
1,057
-649
-38% -$31.2K ﹤0.01% 1591
2026
Q1 		$88.2K Sell
1,706
-1,182
-41% -$60.2K ﹤0.01% 1433
2025
Q4 		$144K Sell
2,888
-12,514
-81% -$608K ﹤0.01% 1405
2025
Q3 		$736K Buy
15,402
+2,090
+16% +$84.2K 0.01% 749
2025
Q2 		$420K Buy
13,312
+534
+4% +$17.1K 0.01% 1005
2025
Q1 		$418K Sell
12,778
-1,784
-12% -$63.2K 0.01% 930
2024
Q4 		$527K Buy
14,562
+14,395
+8,620% +$507K 0.01% 876
2024
Q3 		$5.21K Buy
+167
New +$5.21K ﹤0.01% 1746

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Sterling Capital Management's SUPN Position: Q2 2026 in Review

Sterling Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 38% in Q2 2026, selling an estimated $31.2K and leaving 1,057 shares worth $49.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

Sterling Capital Management first reported a position in SUPN in Q3 2024 and has held it in 8 quarters since. The position peaked at $736K in Q3 2025. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Sterling Capital Management held 1,057 shares of Supernus Pharmaceuticals worth $49.2K as of Q2 2026.
  • Sterling Capital Management sold 649 Supernus Pharmaceuticals shares in Q2 2026, an estimated $31.2K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1591 holding.
  • Sterling Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Supernus Pharmaceuticals position peaked at $736K in Q3 2025.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.